Conditions: Liver Cancer; Pancreas Cancer; Stomach Cancer; Bile Duct Cancer
Intervention: Device: Endovascular Denervation
Sponsor: Shanghai Golden Leaf MedTec Co. Ltd
Not yet recruiting
Feeds
32378 items (32378 unread) in 74 feeds
Acinar Cell Carcinoma
(227 unread)
Acinic Cell Carcinoma
(127 unread)
Adenoid Cystic Carcinoma
(705 unread)
Adrenal Gland Cancer
(2666 unread)
Ampulla Of Vater
(958 unread)
Anal Cancer
(3342 unread)
Angiosarcoma
(1002 unread)
Appendix Cancer
(438 unread)
Bile Duct Cancer
(3816 unread)
Brain and CNS
(4383 unread)
Carcinoid
(1375 unread)
Endocrine/Neuroendocrine
(3718 unread)
Gall Bladder Cancer
(1447 unread)
Hemangioendothelioma
(317 unread)
Hepatoblastoma
(515 unread)
Pancreas
(425 unread)
Phyllodes
(259 unread)
PMP and Mucinous Tumors
(314 unread)
Rhabdomyosarcoma
(1171 unread)
Sarcoma
(5173 unread)
Trial - Cholangiocarcinoma (95 unread)
-
A Clinical Trial to Evaluate Safety and Efficacy of Endovascualr Denervation in Treatment of Cancer Pain
Posted: July 10th, 2019, 2:00pm GMT
-
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
Posted: July 1st, 2019, 2:00pm GMT
Condition: Biliary Tract Carcinoma
Interventions: Drug: Pembrolizumab; Drug: Gemcitabine; Drug: Cisplatin; Drug: Placebo
Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting -
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
Posted: June 27th, 2019, 2:00pm GMT
Conditions: Peripheral T Cell Lymphoma; Diffuse Large B Cell Lymphoma; Biliary Tract Cancer; Extranodal NK T Cell Lymphoma, Nasal
Intervention: Biological: STI-3031
Sponsor: Sorrento Therapeutics, Inc.
Not yet recruiting -
Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma
Posted: June 24th, 2019, 2:00pm GMT
Condition: Advanced Cholangiocarcinoma
Interventions: Drug: Anlotinib; Drug: TQB2450
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Not yet recruiting -
Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors
Posted: June 19th, 2019, 2:00pm GMT
Conditions: Glioma; Cholangiocarcinoma; Solid Tumor; IDH Mutation
Interventions: Drug: Olaparib; Drug: Durvalumab
Sponsor: University Health Network, Toronto
Not yet recruiting -
CT Perfusion Scans in Detecting Changes in Blood Flow to the Liver After Portal Vein Embolization
Posted: June 19th, 2019, 2:00pm GMT
Condition: Liver and Intrahepatic Bile Duct Carcinoma
Interventions: Radiation: Computed Tomography Perfusion Imaging; Procedure: Liver Biopsy
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting -
Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma
Posted: June 11th, 2019, 2:00pm GMT
Condition: Advanced Cholangiocarcinoma
Interventions: Drug: Toripalimab; Drug: Gemcitabine; Drug: 5- fluorine pyrimidine
Sponsor: Jiangmen Central Hospital
Not yet recruiting -
Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
Posted: May 15th, 2019, 2:00pm GMT
Condition: Cholangiocarcinoma, Intrahepatic
Intervention: Drug: combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001)
Sponsor: Shanghai Zhongshan Hospital
Recruiting -
Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer
Posted: May 9th, 2019, 2:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Drug: nab-paclitaxel
Sponsor: Istituto Clinico Humanitas
Recruiting -
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Posted: May 8th, 2019, 2:00pm GMT
Conditions: Stage III Hepatocellular Carcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Unresectable Hepatocellular Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Radiation: External Beam Radiation Therapy; Biological: Pneumococcal 13-valent Conjugate Vaccine; Biological: Therapeutic Autologous Dendritic Cells
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting -
Treatment of Advanced Intrahepatic Cholangiocarcinoma
Posted: May 7th, 2019, 2:00pm GMT
Condition: ICC
Interventions: Drug: Levamisole Hydrochloride; Drug: Anlotinib Hydrochloride Capsules
Sponsors: The First Affiliated Hospital of Zhengzhou University; First Affiliated Hospital of Xinjiang Medical University; Luoyang Central Hospital; Nanyang Central Hospital; Anyang Tumor Hospital; Third People's Hospital of Jiaozuo; Sanmenxia Central Hospital; pinmei Group General Hospital
Recruiting -
Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer
Posted: May 6th, 2019, 2:00pm GMT
Condition: Biliary Tract Cancer
Interventions: Biological: 'SMT-NK' Inj (allogeneic Natural Killer cell); Drug: Pembrolizumab Injection [Keytruda]
Sponsor: SMT bio Co., Ltd.
Not yet recruiting -
Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer
Posted: April 9th, 2019, 2:00pm GMT
Conditions: Mesothelioma; Mesothelioma, Malignant; Mesothelioma; Pleura; Mesotheliomas Pleural; Mesothelioma Peritoneum; Cholangiocarcinoma; Cholangiocarcinoma Recurrent; Ovarian Cancer; Non Small Cell Lung Cancer; Non Small Cell Lung Cancer Metastatic
Interventions: Drug: TC-210 T Cells; Drug: fludarabine; Drug: cyclophosphamide; Biological: anti-PD1
Sponsor: TCR2 Therapeutics
Recruiting -
Combination of Radiotherapy With Anti PD-1/PD-L1 Antibodies for Unresectable ICC
Posted: April 2nd, 2019, 2:00pm GMT
Conditions: Intrahepatic Cholangiocarcinoma; Radiotherapy; Immunotherapy
Interventions: Combination Product: SBRT+anti-PD-1; Drug: Gemcitabine+cisplatin
Sponsor: Sun Yat-sen University
Not yet recruiting -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Posted: April 1st, 2019, 2:00pm GMT
Conditions: Cancer, All Types; Cancer of Liver; Cancer of Stomach; Cancer of Head and Neck; Cancer of Rectum; Cancer of Kidney; Cancer of Esophagus; Cancer of Colon; Cancer Skin; Cancer of Cervix; Cancer, Metastatic; Cancer of Larynx; Cancer of Neck; Cancer of Lung; Cancer of Brain and Nervous System; Cancer of Vulva, Disseminated; Cancer of Pancreas; Sarcoma; GIST; Small-cell Lung Cancer; Adenocarcinoma Lung; Cancer of Prostate; Cancer, Advanced; Adrenal Cancer; Testicular Cancer; Uterine Cancer; Bronchoalveolar Cell Lung Cancer; Cancer Unknown Primary; Glioblastoma Multiforme; Oligodendroglioma; Breast Cancer; Renal Cell Carcinoma; Hepatocellular Carcinoma; Cholangiocarcinoma; Squamous Cell Carcinoma; Transitional Cell Carcinoma; Cancer, Other; Cancer, Anal; Melanoma; Cancer, Bile Duct; Cancer, Bladder; Cancer Cords Vocal; Cancers Cell Neuroendocrine; Cancer Differentiated Poorly; Cancer, Anaplastic Thyroid
Intervention:
Sponsors: SpeciCare; Dana-Farber Cancer Institute; Kalispell Regional Medical Center; Georgia Institute of Technology; Ontario Institute for Cancer Research; SEngine Precision Medicine; Helomics
Recruiting -
Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors
Posted: March 29th, 2019, 2:00pm GMT
Conditions: Liver Neoplasm Malignant Primary; Cholangiocarcinoma; Combinational Immunotherapy; Biomarker
Intervention: Drug: Lenvatinib plus Pembrolizumab
Sponsor: Peking Union Medical College Hospital
Not yet recruiting -
Olaparib and Ceralasertib in Treating Patients With IDH Mutant Cholangiocarcinoma or Solid Tumors
Posted: March 18th, 2019, 2:00pm GMT
Conditions: IDH1 Gene Mutation; IDH2 Gene Mutation; Malignant Solid Neoplasm; Progressive Disease; Refractory Cholangiocarcinoma; Refractory Malignant Solid Neoplasm
Interventions: Drug: Ceralasertib; Drug: Olaparib
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Posted: March 13th, 2019, 2:00pm GMT
Conditions: Solid Tumor; Colon Cancer; Cholangiocarcinoma; Bladder Cancer; Ovarian Cancer; Gastric Cancer; Palpable Subcutaneous Malignant Lesions
Interventions: Biological: TRK-950; Drug: Irinotecan; Drug: Leucovorin; Drug: 5-FU; Drug: Gemcitabine; Drug: Cisplatin; Drug: Carboplatin; Biological: Ramucirumab; Drug: Paclitaxel; Biological: Nivolumab; Biological: Pembrolizumab; Drug: Imiquimod Cream
Sponsor: Toray Industries, Inc
Recruiting -
Toripalimab or Placebo as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Posted: March 8th, 2019, 3:00pm GMT
Condition: Epatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Intervention: Biological: TORIPALIMAB INJECTION(JS001 )
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Not yet recruiting -
Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images
Posted: February 25th, 2019, 3:00pm GMT
Conditions: Gallstone; Cholangitis; Cholangiocarcinoma; Pancreatitis; Pancreatic Ductal Adenocarcinoma
Intervention: Other: ultra-rapid acquisition of bile ducts images
Sponsor: IHU Strasbourg
Recruiting -
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
Posted: February 7th, 2019, 3:00pm GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer
Intervention: Drug: M7824
Sponsors: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany
Recruiting -
TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced Cancers
Posted: February 4th, 2019, 3:00pm GMT
Conditions: Hepatocellular Carcinoma; Metastatic Castration Resistant Prostate Cancer; Renal Cell Carcinoma; Non-small Cell Lung Cancer; Colorectal Cancer; Squamous Cell Carcinoma of Head and Neck; Triple-Negative Breast Cancer; Urothelial Carcinoma; Cholangiocarcinoma; GastroEsophageal Cancer; Pancreatic Cancer; Sarcoma
Interventions: Drug: Part 1 TPST-1120; Drug: Part 2a TPST-1120 + nivolumab; Drug: Part 2b TPST-1120 + docetaxel; Drug: Part 2c TPST-1120 + cetuximab; Drug: Part 3 TPST-1120; Drug: Part 4a TPST-1120 + nivolumab; Drug: Part 4b TPST-1120 + docetaxel; Drug: Part 4c TPST-1120 + cetuximab
Sponsor: Tempest Therapeutics
Recruiting -
Clinical Trial of Autologous Tcm Immunotherapy in ICC
Posted: January 29th, 2019, 3:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Biological: autologous Tcm cellular immunotherapy
Sponsors: Newish Technology (Beijing) Co., Ltd.; Peking Union Medical College Hospital
Not yet recruiting -
A Phase 1 Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
Posted: January 29th, 2019, 3:00pm GMT
Condition: HER2-expressing Cancers
Intervention: Drug: ZW49
Sponsor: Zymeworks Inc.
Recruiting -
Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer
Posted: January 28th, 2019, 3:00pm GMT
Conditions: Gastric Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Unresectable Esophageal Carcinoma; Unresectable Pancreatic Carcinoma
Intervention: Dietary Supplement: Zinc
Sponsor: Emory University
Recruiting -
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Posted: January 14th, 2019, 3:00pm GMT
Conditions: Colon Cancer; Pancreatic Cancer; Cholangiocarcinoma; Mestatic Colon Carcinoma; Liver Metastasis
Interventions: Drug: MVT-5873; Procedure: pancreatectomy or hepatectomy
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
Posted: January 11th, 2019, 3:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Intervention: Drug: Lenvatinib
Sponsor: Sun Yat-sen University
Recruiting -
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
Posted: January 11th, 2019, 3:00pm GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Biliary Tract Neoplasms
Intervention: Biological: Tumor Infiltrating Lymphocytes (TIL)
Sponsor: Udai Kammula
Recruiting -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
Posted: December 20th, 2018, 3:00pm GMT
Conditions: Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Liver Metastases
Intervention: Drug: MIV-818
Sponsor: Medivir
Recruiting -
Phase 3 Study of BJG398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
Posted: December 12th, 2018, 3:00pm GMT
Conditions: Advanced Cholangiocarcinoma; FGFR2 Gene Mutation
Interventions: Drug: BGJ398; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: QED Therapeutics, Inc.
Recruiting -
Trial of IRE in Cholangiocarcinoma
Posted: December 7th, 2018, 3:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Device: IRE Device
Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting -
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
Posted: December 7th, 2018, 3:00pm GMT
Conditions: Stage III Distal Bile Duct Cancer AJCC v8; Stage III Gallbladder Cancer AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Distal Bile Duct Cancer AJCC v8; Stage IIIA Gallbladder Cancer AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Distal Bile Duct Cancer AJCC v8; Stage IIIB Gallbladder Cancer AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Gallbladder Cancer AJCC v8; Stage IVB Gallbladder Cancer AJCC v8; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Cisplatin; Drug: Gemcitabine Hydrochloride; Drug: Nab-paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting -
Cholangioscopy in Primary Sclerosing Cholangitis (PSC)
Posted: December 5th, 2018, 3:00pm GMT
Condition: Primary Sclerosing Cholangitis (PSC)
Intervention: Device: SpyGlass DS I - II
Sponsor: Boston Scientific Corporation
Recruiting -
A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors
Posted: November 8th, 2018, 3:00pm GMT
Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Gastric Cancer; Esophageal Cancer; Colorectal Cancer
Intervention: Drug: ZSP1241
Sponsor: Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Recruiting -
Primary EUS-GBD in Patients With Unresectable Malignant Biliary Obstruction and Cystic Duct Orifice Involvement.
Posted: November 5th, 2018, 3:00pm GMT
Condition: Acute Cholecystitis
Interventions: Procedure: EUS-guided gallbladder drainage; Procedure: Non EUS-guided gallbladder drainage
Sponsor: Instituto Ecuatoriano de Enfermedades Digestivas
Recruiting -
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Posted: October 3rd, 2018, 2:00pm GMT
Conditions: Colorectal Cancer; Cholangiocarcinoma
Interventions: Device: Medtronic pump and Codman catheter; Drug: Floxuridine (FUDR); Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Irinotecan (CPT-11); Drug: Fluorouracil; Drug: Anti-EGFR (Panitumumab or Cetuximab)
Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting -
A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Posted: September 26th, 2018, 2:00pm GMT
Conditions: Cohort 1a and 1b: Glioma; Cohort 1a and 1b: Glioblastoma Multiforme; Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas); Cohort 3a and 3b: Chondrosarcoma; Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma; Cohort 5a: Other Solid Tumors With IDH1 Mutations
Interventions: Drug: FT-2102; Drug: Azacitidine; Biological: Nivolumab; Drug: Gemcitabine and Cisplatin
Sponsor: Forma Therapeutics, Inc.
Recruiting -
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)
Posted: September 3rd, 2018, 2:00pm GMT
Conditions: Unresectable Cholangiocarcinoma; Metastatic Cholangiocarcinoma
Interventions: Drug: Pemigatinib; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: Incyte Corporation
Recruiting -
Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members
Posted: August 2nd, 2018, 2:00pm GMT
Condition: Gastrointestinal Cancer
Interventions: Other: Surgeon-palliative care team co management; Other: Surgeon team alone management
Sponsors: Stanford University; Patient-Centered Outcomes Research Institute
Recruiting -
Prospective Surveillance for Very Early Hepatocellular Carcinoma
Posted: July 17th, 2018, 2:00pm GMT
Condition: Carcinoma, Hepatocellular
Intervention:
Sponsor: Eastern Hepatobiliary Surgery Hospital
Recruiting -
Ph1 Dose Escalation Study of EOC317 in Chinese Patients With Advanced Solid Tumors
Posted: July 11th, 2018, 2:00pm GMT
Condition: Solid Tumor
Intervention: Drug: EOC317
Sponsor: EddingPharm Oncology Co., LTD.
Recruiting -
Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
Posted: July 9th, 2018, 2:00pm GMT
Conditions: Resectable Cholangiocarcinoma; Stage IB Intrahepatic Cholangiocarcinoma AJCC v8; Stage II Intrahepatic Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Nab-paclitaxel
Sponsors: Emory University; Celgene
Recruiting -
Improving Outcomes in Cancer Patients With a Nutritional and Physical Conditioning Prehabilitation Program
Posted: March 23rd, 2018, 2:00pm GMT
Conditions: Pancreatic Cancer; Liver Cancer; Bile Duct Cancer; Hepatobiliary Cancer; Surgery
Interventions: Other: Exercise; Other: Nutrition; Behavioral: Relaxation techniques
Sponsors: McGill University Health Center; Dr. Franco Carli
Recruiting -
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Posted: March 2nd, 2018, 3:00pm GMT
Conditions: Cancer, Metastatic; Cancer; Cancer of Pancreas; Cancer of Liver; Cancer of Stomach; Cancer Liver; Cancer of Rectum; Cancer of Kidney; Cancer of Esophagus; Cancer of Cervix; Cancer of Colon; Cancer of Larynx; Cancer, Lung; Cancer, Breast; Cancer, Advanced; Cancer Prostate; Cancer of Neck; Cancer of Skin; Neuroendocrine Tumors; Carcinoma; Mismatch Repair Deficiency; BRCA Gene Rearrangement; Non Hodgkin Lymphoma; Leukemia; Non Small Cell Lung Cancer; Cholangiocarcinoma; Glioblastoma; Central Nervous System Tumor; Melanoma; Urothelial Carcinoma; Bladder Cancer; Ovarian Cancer; Endometrial Cancer; Testicular Cancer; Breast Cancer
Intervention: Other: Clinical Trial Matching
Sponsor: Massive Bio, Inc.
Recruiting -
Fluorescence QRH-882260 Peptide Imaging in the Bile Duct
Posted: February 19th, 2018, 3:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Drug: QRH-882260 Heptapeptide
Sponsors: D. Kim Turgeon, MD; University of Washington
Not yet recruiting -
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Posted: February 6th, 2018, 3:00pm GMT
Conditions: Breast Cancer; Colorectal Cancer; Cholangiocellular Carcinoma; Sarcoma; Desmoid Tumour; Adenoid Cystic Carcinoma; Non-hodgkin Lymphoma; Glomus Tumor, Malignant
Intervention: Drug: CB-103
Sponsor: Cellestia Biotech AG
Recruiting -
Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer
Posted: January 24th, 2018, 3:00pm GMT
Conditions: Liver Cancer; Liver Metastases
Intervention: Radiation: SBRT
Sponsor: Centre Oscar Lambret
Recruiting -
A Study of ABC294640 (Yeliva ®) in the Treatment of Patients With Advanced Cholangiocarcinoma
Posted: December 19th, 2017, 3:00pm GMT
Conditions: Cholangiocarcinoma; Cholangiocarcinoma Non-resectable; Cholangiocarcinoma, Perihilar; Cholangiocarcinoma, Extrahepatic; Cholangiocarcinoma, Intrahepatic
Intervention: Drug: ABC294640
Sponsor: RedHill Biopharma Limited
Recruiting -
Multiorgan Metabolic Imaging Response Assessment of Abemaciclib
Posted: November 13th, 2017, 3:00pm GMT
Conditions: Esophageal Adenocarcinoma; Esophagus SCC; Cholangiocarcinoma; Urothelial/Bladder Cancer, Nos; Endometrial Cancer
Intervention: Drug: Abemaciclib
Sponsors: Jules Bordet Institute; Eli Lilly and Company
Recruiting -
A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Posted: November 6th, 2017, 3:00pm GMT
Conditions: Melanoma; Non-small Cell Lung Cancer; Breast Cancer; Gastric Cancer; Renal Cell Carcinoma; Ovarian Cancer; Cholangiocarcinoma; Bladder Urothelial Carcinoma; Pancreatic Adenocarcinoma; Colorectal Cancer; Esophageal Cancer; Hepatic Cancer; Head and Neck Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Other Solid Tumors; Diffuse Large B-cell Lymphoma (DLBCL); Mantle Cell Lymphoma; Indolent B-cell Lymphomas; Non-Hodgkin Lymphoma
Interventions: Drug: CDX-1140; Drug: CDX-301
Sponsor: Celldex Therapeutics
Recruiting -
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
Posted: August 22nd, 2017, 2:00pm GMT
Conditions: Extrahepatic Bile Duct Adenocarcinoma, Biliary Type; Gallbladder Adenocarcinoma, Biliary Type; Metastatic Pancreatic Adenocarcinoma; Recurrent Cholangiocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Gallbladder Cancer AJCC V7; Stage III Hepatocellular Carcinoma AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage IVB Hepatocellular Carcinoma AJCC v7; Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7; Unresectable Gallbladder Carcinoma; Unresectable Pancreatic Carcinoma
Interventions: Biological: Durvalumab; Drug: Guadecitabine
Sponsors: University of Southern California; National Cancer Institute (NCI); Van Andel Research Institute
Recruiting -
A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
Posted: August 15th, 2017, 2:00pm GMT
Conditions: Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Cancer; Cholangiocarcinoma; Pancreatic Cancer; Metastatic Pancreatic Cancer
Interventions: Drug: Entinostat; Drug: Nivolumab
Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Syndax Pharmaceuticals; Bristol-Myers Squibb
Recruiting -
Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers
Posted: July 12th, 2017, 2:00pm GMT
Conditions: Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Sarcoma; Colorectal Neoplasms; Salivary Gland Neoplasms; Biliary Tract Neoplasms; Brain Neoplasm, Primary; Melanoma; Glioblastoma; Bile Duct Neoplasms; Astrocytoma; Head and Neck Squamous Cell Carcinoma; Pontine Glioma; Pancreatic Neoplasms; Ovarian Neoplasms; Carcinoma, Renal Cell; Cholangiocarcinoma; Skin Carcinoma; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Intestinal Neoplasms; Thyroid Cancer; GIST; Malignant Peripheral Nerve Sheath Tumors; Breast Secretory Carcinoma; Uterine Neoplasms; Fibrosarcoma; Infantile Fibrosarcoma; Congenital Mesoblastic Nephroma; Central Nervous System Neoplasms
Intervention: Drug: LOXO-195
Sponsor: Bayer
Recruiting -
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
Posted: June 7th, 2017, 2:00pm GMT
Conditions: Autoimmune Liver Disease; Autoimmune Hepatitis; Primary Sclerosing Cholangitis
Intervention:
Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting -
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
Posted: May 11th, 2017, 2:00pm GMT
Conditions: Solid Tumor, Adult; Breast Cancer; Non Small Cell Lung Cancer; Prostate Cancer; Ovarian Cancer; Endometrial Cancer; Head and Neck Cancer; Cholangiocarcinoma
Intervention: Drug: CX-2009
Sponsor: CytomX Therapeutics
Recruiting -
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Posted: May 9th, 2017, 2:00pm GMT
Conditions: Hepatocellular Carcinoma (HCC); Cholangiocarcinoma; Esophageal Cancer; Nasopharyngeal Cancer; Ovarian Cancer; Solid Tumors
Intervention: Drug: INCB062079
Sponsor: Incyte Corporation
Recruiting -
Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer
Posted: May 3rd, 2017, 2:00pm GMT
Conditions: Colon Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Pancreatic Carcinoma
Interventions: Procedure: Biospecimen Collection; Other: Laboratory Biomarker Analysis; Other: Laboratory Procedure
Sponsors: University of Southern California; National Cancer Institute (NCI)
Recruiting -
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Posted: April 13th, 2017, 2:00pm GMT
Conditions: Biliary Tract Neoplasms; Cholangiocarcinoma; Bile Duct Cancer; Liver Cancer; Gallbladder Cancer
Interventions: Biological: Pembrolizumab (MK-3475); Drug: Oxaliplatin; Drug: Capecitabine
Sponsor: National Cancer Institute (NCI)
Recruiting -
Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma
Posted: April 7th, 2017, 2:00pm GMT
Condition: Cholangitis
Intervention: Procedure: Injection of 37℃ contrast agent
Sponsor: Hepatopancreatobiliary Surgery Institute of Gansu Province
Recruiting -
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Posted: March 7th, 2017, 3:00pm GMT
Condition: Advanced Solid Tumors Cancer
Interventions: Drug: ABBV-368; Drug: ABBV-181
Sponsor: AbbVie
Recruiting -
Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer
Posted: February 7th, 2017, 3:00pm GMT
Conditions: Adenocarcinoma Metastatic; Biliary Tract Cancer; Adenocarcinoma of the Biliary Tract; Adenocarinoma Locally Advanced; Non-Resectable Hepatocellular Carcinoma; Intrahepatic Bile Duct Carcinoma; Extrahepatic Bile Duct Carcinoma
Interventions: Drug: Arm NaI-IRI + 5-FU + Leucovorin (Arm A); Drug: Arm Cisplatin + Gemcitabine (Arm B)
Sponsors: AIO-Studien-gGmbH; SERVIER (Shire, Baxalta); Institut für Klinisch-Onkologische Forschung (IKF) am Krankenhaus Nordwest GmbH
Recruiting -
Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies
Posted: February 6th, 2017, 3:00pm GMT
Conditions: Cholangiocarcinoma Non-resectable; Cholangiocarcinoma Metastatic; Cholangiocarcinoma of the Gallbladder; Cholangiocarcinoma Advanced
Interventions: Drug: nal-IRI; Drug: 5-FU; Drug: leucovorin
Sponsors: AIO-Studien-gGmbH; SERVIER (Shire)
Recruiting -
A Study of ABBV-181 in Participants With Advanced Solid Tumors
Posted: December 22nd, 2016, 3:00pm GMT
Condition: Advanced Solid Tumors
Interventions: Drug: Rovalpituzumab Tesirine; Drug: ABBV-181
Sponsor: AbbVie
Recruiting -
A Study of TRK-950 in Patients With Advanced Solid Tumors
Posted: December 13th, 2016, 3:00pm GMT
Conditions: Locally Advanced or Metastatic Solid Carcinomas; Colon Cancer; Cholangiocarcinoma
Intervention: Biological: TRK-950
Sponsor: Toray Industries, Inc
Recruiting -
Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies
Posted: November 10th, 2016, 3:00pm GMT
Condition: Malignancies Multiple
Interventions: Drug: Anti-PD-1 antibody; Drug: Decitabine; Drug: Chemotherapy
Sponsor: Han weidong
Recruiting -
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
Posted: October 5th, 2016, 2:00pm GMT
Conditions: Gastrointestinal Cancer; Neuroendocrine Tumours; Malignant Female Reproductive System Neoplasm
Interventions: Drug: Ipilimumab; Drug: Nivolumab
Sponsors: Olivia Newton-John Cancer Research Institute; Bristol-Myers Squibb
Recruiting -
Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery
Posted: August 29th, 2016, 2:00pm GMT
Conditions: Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Stage IV Liver Cancer; Stage IVA Liver Cancer; Stage IVB Liver Cancer; Vascular Thrombosis
Interventions: Procedure: Computed Tomography; Procedure: Single Photon Emission Computed Tomography; Drug: Technetium Tc-99m Sulfur Colloid
Sponsors: University of Washington; National Cancer Institute (NCI)
Recruiting -
Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy
Posted: August 3rd, 2016, 2:00pm GMT
Conditions: Gastric Cancer; Pancreas Cancer; Bile Duct Cancer; Gastroesophageal Cancer; Esophageal Cancer
Interventions: Behavioral: Early Palliative Care visit; Other: EORTC-QLQ-C30 questionnaire; Other: HADS score
Sponsors: Centre Oscar Lambret; Ligue contre le cancer, France; Région Nord-Pas de Calais, France; National Cancer Institute, France
Recruiting -
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
Posted: July 15th, 2016, 2:00pm GMT
Conditions: Advanced Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Hepatocellular Carcinoma; Liver Cancer; Liver Neoplasms; Hepatic Cancer; Hepatic Carcinoma; Cholangiocarcinoma; Bile Duct Cancer
Intervention: Drug: H3B-6527
Sponsors: H3 Biomedicine Inc.; Eisai Inc.
Recruiting -
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Posted: July 4th, 2016, 2:00pm GMT
Conditions: Biliary Tract Neoplasms; Liver Cancer; Hepatocellular Carcinoma; Cholangiocarcinoma; Bile Duct Cancer
Interventions: Drug: Durvalumab; Drug: Tremelimumab; Procedure: TACE; Procedure: RFA; Procedure: Cryoablation
Sponsor: National Cancer Institute (NCI)
Recruiting -
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
Posted: May 2nd, 2016, 2:00pm GMT
Conditions: Colorectal Adenocarcinoma; Metastatic Cholangiocarcinoma; Metastatic Colorectal Carcinoma; Metastatic Digestive System Carcinoma; Metastatic Esophageal Carcinoma; Metastatic Gastric Carcinoma; Metastatic Pancreatic Adenocarcinoma; Stage IV Colorectal Cancer AJCC v7; Stage IV Esophageal Cancer AJCC v7; Stage IV Gastric Cancer AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7
Interventions: Biological: Adoptive Immunotherapy; Biological: Aldesleukin; Drug: Cyclophosphamide; Other: Laboratory Biomarker Analysis; Biological: Pembrolizumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Not yet recruiting -
High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
Posted: May 2nd, 2016, 2:00pm GMT
Conditions: Acinar Cell Carcinoma; Ampulla of Vater Adenocarcinoma; Cholangiocarcinoma; Duodenal Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type; Periampullary Adenocarcinoma
Interventions: Procedure: Pancreatectomy; Other: Lavage
Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Recruiting -
Quality of Life in Patients With Primary Sclerosing Cholangitis
Posted: March 18th, 2016, 2:00pm GMT
Condition: Primary Sclerosing Cholangitis
Intervention: Other: quality of life survey
Sponsor: Duke University
Recruiting -
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cho
Posted: March 4th, 2016, 3:00pm GMT
Condition: Neoplasm
Intervention: Drug: Erdafitinib
Sponsor: Janssen Research & Development, LLC
Recruiting -
Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study
Posted: February 19th, 2016, 3:00pm GMT
Condition: Localized Non-Resectable Adult Liver Carcinoma
Intervention: Other: Yttrium-90 Resin Microspheres
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting -
A Study for Efficacy of Side-by-side Compared to Stent-in-stent Technique in the Endoscopic Management of Malignant Hilar Biliary Obstruction
Posted: January 20th, 2016, 3:00pm GMT
Conditions: Cholangiocarcinoma; Gallbladder Cancer; Pancreatic Cancer; HCC; AOV Cancer
Interventions: Procedure: side by side; Procedure: stent in stent
Sponsor: Yonsei University
Recruiting -
Efficacy and Safety of Endobiliary Radiofrequency Ablation by Using a Novel RF Catheter (ELRA®) on Maintaining the Patency of Endobiliary Metal Drainage in Patients With Malignant Biliary Strictures : A Double-arm Comparable Study
Posted: January 5th, 2016, 3:00pm GMT
Condition: Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer
Interventions: Device: Radiofrequency ablation with stenting; Device: stenting
Sponsor: Yonsei University
Recruiting -
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
Posted: December 16th, 2015, 3:00pm GMT
Conditions: Biliary Carcinoma; Gall Bladder Carcinoma; Cholangiocarcinoma; Gastrointestinal Tumor
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Copanlisib
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Bayer
Recruiting -
Phase I Trial of Radiation Therapy in Patients With Liver Cancers and Impaired Liver Function
Posted: December 10th, 2015, 3:00pm GMT
Conditions: Cholangiocarcinoma; Cirrhosis; Hepatocellular Carcinoma; Metastatic Malignant Neoplasm in the Liver
Interventions: Other: Laboratory Biomarker Analysis; Procedure: Magnetic Resonance Imaging; Radiation: Radiation Therapy; Other: Survey Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting -
Bile Usefulness for Detecting IgG4-related Sclerosing Cholangitis
Posted: November 30th, 2015, 3:00pm GMT
Conditions: IgG4-related Sclerosing Cholangitis; IgG4-related Disease
Intervention:
Sponsors: Mayo Clinic; Nagoya University
Recruiting -
Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
Posted: October 15th, 2015, 2:00pm GMT
Conditions: Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Sarcoma; Colorectal Neoplasms; Salivary Gland Neoplasms; Biliary Tract Neoplasms; Brain Neoplasm, Primary; Carcinoma, Ductal, Breast; Melanoma; Solid Tumors; Glioblastoma; Bile Duct Neoplasms; Astrocytoma; Head and Neck Squamous Cell Carcinoma; Pontine Glioma; Pancreatic Neoplasms; Ovarian Neoplasms; Carcinoma, Renal Cell; Cholangiocarcinoma; Carcinoma; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas
Intervention: Drug: Larotrectinib LOXO-101
Sponsors: Bayer; Loxo Oncology, Inc.
Recruiting -
OLAParib COmbinations
Posted: October 15th, 2015, 2:00pm GMT
Condition: Cancer
Interventions: Drug: AZD2281; Drug: AZD5363; Drug: AZD1775; Drug: AZD6738
Sponsors: Joseph Paul Eder; Dana-Farber Cancer Institute; Vanderbilt-Ingram Cancer Center; The Cleveland Clinic
Recruiting -
Lipidomics, Proteomics, Micro RNAs and Volatile Organic Compounds (VOC)
Posted: August 24th, 2015, 2:00pm GMT
Condition: Pancreatic Neoplasms
Intervention: Other: blood and bile
Sponsor: Florida Hospital
Recruiting -
Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
Posted: August 11th, 2015, 2:00pm GMT
Conditions: Cholangiocarcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Stage III Gallbladder Cancer AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7; Unresectable Gallbladder Carcinoma
Interventions: Other: Laboratory Biomarker Analysis; Biological: Ramucirumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting -
90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Posted: July 31st, 2015, 2:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Device: SIR-Spheres microspheres (Yttrium-90 Microspheres); Drug: Gemcitabine; Drug: Cisplatin
Sponsor: Medical University of South Carolina
Recruiting -
A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer
Posted: May 27th, 2015, 2:00pm GMT
Condition: Solid Tumor
Intervention: Biological: FF21101
Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc.
Recruiting -
Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies - (FIGHT-101)
Posted: March 19th, 2015, 2:00pm GMT
Conditions: Lung Cancer; Solid Tumor; Gastric Cancer; Urothelial Cancer; Endometrial Cancer; Multiple Myeloma; Myeloproliferative Neoplasms; Breast Cancer; Cholangiocarcinoma; UC; MPN
Interventions: Drug: Pemigatinib; Drug: Gemcitabine + Cisplatin; Drug: Pembrolizumab; Drug: Docetaxel; Drug: Trastuzumab; Drug: INCMGA00012
Sponsor: Incyte Corporation
Recruiting -
Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L
Posted: September 5th, 2014, 2:00pm GMT
Conditions: Hepatocellular Carcinoma; HCC; Liver Cancer
Interventions: Biological: hepcortespenlisimut-L; Biological: Placebo
Sponsor: Immunitor LLC
Recruiting -
Liver Resection Versus Radio-chemotherapy-Transplantation for Hilar Cholangiocarcinoma
Posted: September 5th, 2014, 2:00pm GMT
Condition: Cholangiocarcinoma
Interventions: Procedure: CAPECITABINE-Radiotherapy -Liver Transplantation; Procedure: RESECTION
Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting -
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer
Posted: June 23rd, 2014, 2:00pm GMT
Conditions: Cholangiocarcinoma; Gall Bladder Carcinoma
Interventions: Drug: Gemcitabine; Drug: Cisplatin; Drug: Capecitabine
Sponsors: Universitätsklinikum Hamburg-Eppendorf; Deutsche Krebshilfe e.V., Bonn (Germany); medac GmbH; Cancer Research UK; Australasian Gastro-Intestinal Trials Group; Dutch Hepatocellular & Cholangiocarcinoma Group (DHCG)
Recruiting -
Treatment for Bile Duct Cancer in the Liver
Posted: June 19th, 2014, 2:00pm GMT
Condition: Cholangio Carcinoma
Intervention: Drug: SIRT Yttrium-90
Sponsor: Chinese University of Hong Kong
Recruiting -
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
Posted: May 30th, 2014, 2:00pm GMT
Conditions: Advanced Cholangiocarcinoma; FGFR2 Gene Mutation
Intervention: Drug: BGJ398 (infigratinib)
Sponsor: QED Therapeutics, Inc.
Recruiting -
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
Posted: May 1st, 2014, 2:00pm GMT
Condition: Cholangiocarcinoma
Interventions: Drug: CX-4945; Drug: Cisplatin; Drug: Gemcitabine
Sponsor: Senhwa Biosciences, Inc.
Recruiting -
A Study of TAS-120 in Patients With Advanced Solid Tumors
Posted: February 3rd, 2014, 3:00pm GMT
Conditions: Cholangiocarcinoma; Brain Tumor; Urothelial Cancer; Other Tumor Types With FGFR2 Gene Fusions; Activating Mutations; FGFR2 Amplification
Intervention: Drug: TAS-120
Sponsor: Taiho Oncology, Inc.
Recruiting -
International Registry on Cholangiocarcinoma Treatment
Posted: August 12th, 2013, 2:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Drug: Doxorubicin
Sponsor: International Group of Endovascular Oncology
Recruiting